Please login to the form below

Not currently logged in
Email:
Password:

UCB submits brivaracetam for use in epilepsy

Files drug in both the US and EU
UCB

Belgian pharma company UCB has filed its investigational drug brivaracetam for approval to treat epilepsy in both the US and EU.

Both the US FDA and the European Medicines Agency (EMA) have accepted brivaracetam for review as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients over 16 years of age.

Dr Iris Loew-Friedrich, chief medical officer and executive VP at UCB, commented: “Today is a major milestone for brivaracetam and an exciting day for everyone at UCB who is committed to its development.

“It is also an important time for the clinicians and patients whose involvement in brivaracetam clinical trials has been so important in helping up to address the need for new treatment options for adult patients who do not achieve partial-onset seizure control with current antiepileptic drugs.”

The filings are supported by data from three phase III studies, which evaluated the efficacy and safety of adjunctive brivaracetam in a 5-200mg daily dosage in patients with uncontrolled partial-onset seizures.

A fourth phase III study evaluated the safety and tolerability of adjunctive brivaracetam given to patients with the same symptoms.

The filing is a major milestone for UCB as it pursues its goal of building its epilepsy business following the loss of patent for Keppra in the US and EU in the past few years.

The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.

Article by
Kirstie Pickering

22nd January 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics